Classification Of Acute Lymphoblastic Leukemia

Trial Information

Classification Of Acute Lymphoblastic Leukemia

OBJECTIVES:

- Provide a classification guide that will organize the clinical and laboratory data
necessary for assigning each patient with newly diagnosed acute lymphoblastic leukemia
(ALL) to a specific treatment clinical trial.

- Provide an administrative base to capture classification data for correlative studies
accompanying current Children's Oncology Group (COG) ALL treatment clinical trials.

- Provide a central reference guide for all required and research only ALL studies that
will be conducted at local and reference laboratories.

- Provide a mechanism for optional banking of leukemia and germline specimens for current
and future research.

OUTLINE: Patients undergo blood collection and bone marrow biopsies at baseline and at the
end of induction therapy for immunophenotyping for marker identification; molecular testing
for translocations; trisomy analysis by fluorescence in situ hybridization (FISH); and DNA
ploidy. Immunophenotype results obtained on this study are used to determine the patient's
assignment to specific treatment clinical trials (consistent with acute lymphoblastic
leukemia).

After completion of induction therapy, patients are followed once or twice annually.